US2022213458A1PendingUtilityA1

Mad nucleases

79
Assignee: INSCRIPTA INCPriority: Jan 4, 2021Filed: Mar 9, 2022Published: Jul 7, 2022
Est. expiryJan 4, 2041(~14.4 yrs left)· nominal 20-yr term from priority
Inventors:Juhan KimBenjamin MijtsAamir Mir
C12N 2800/80C12N 2310/20C12N 15/113C12N 9/22C12Y 301/21004C12N 15/907C12N 2320/50C12N 15/11
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides new RNA-guided nuclease systems and engineered nickases for making rational, direct edits to nucleic acids in live cells.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A system for CRISPR editing of live cells comprising a MAD2015 nuclease having a sequence SEQ ID NO: 1, a CRISPR repeat RNA having a sequence SEQ ID NO: 2, and a tracr RNA having a sequence SEQ ID NO: 3; a MAD2016 nuclease having a sequence SEQ ID NO: 4, a CRISPR repeat RNA having a sequence SEQ ID NO: 5, and a tracr RNA having a sequence SEQ ID NO: 6; a MAD2017 nuclease having a sequence SEQ ID NO: 7, a CRISPR repeat RNA having a sequence SEQ ID NO: 8, and a tracr RNA having a sequence SEQ ID NO: 9; a MAD2019 nuclease having a sequence SEQ ID NO: 10, a CRISPR repeat RNA having a sequence SEQ ID NO: 11, and a tracr RNA having a sequence SEQ ID NO: 12; a MAD2020 nuclease having a sequence SEQ ID NO: 13, a CRISPR repeat RNA having a sequence SEQ ID NO: 14, and a tracr RNA having a sequence SEQ ID NO: 15; a MAD2021 nuclease having a sequence SEQ ID NO: 16, a CRISPR repeat RNA having a sequence SEQ ID NO: 17, and a tracr RNA having a sequence SEQ ID NO: 18; or a MAD2022 nuclease having a sequence SEQ ID NO: 19, a CRISPR repeat RNA having a sequence SEQ ID NO: 20, and a tracr RNA having a sequence SEQ ID NO: 21. 
     
     
         2 . The system for CRISPR editing of live cells of  claim 1 , comprising a MAD2015 nuclease having a sequence SEQ ID NO: 1, a CRISPR repeat RNA having a sequence SEQ ID NO: 2, and a tracr RNA having a sequence SEQ ID NO: 3. 
     
     
         3 . The system for CRISPR editing of live cells of  claim 1 , comprising a MAD2016 nuclease having a sequence SEQ ID NO: 4, a CRISPR repeat RNA having a sequence SEQ ID NO: 5, and a tracr RNA having a sequence SEQ ID NO: 6. 
     
     
         4 . The system for CRISPR editing of live cells of  claim 1 , comprising a MAD2017 nuclease having a sequence SEQ ID NO: 7, a CRISPR repeat RNA having a sequence SEQ ID NO: 8, and a tracr RNA having a sequence SEQ ID NO: 9. 
     
     
         5 . The system for CRISPR editing of live cells of  claim 1 , comprising a MAD2019 nuclease having a sequence SEQ ID NO: 10, a CRISPR repeat RNA having a sequence SEQ ID NO: 11, and a tracr RNA having a sequence SEQ ID NO: 12. 
     
     
         6 . The system for CRISPR editing of live cells of  claim 1 , comprising a MAD2020 nuclease having a sequence SEQ ID NO: 13, a CRISPR repeat RNA having a sequence SEQ ID NO: 14, and a tracr RNA having a sequence SEQ ID NO: 15. 
     
     
         7 . The system for CRISPR editing of live cells of  claim 1 , comprising a MAD2021 nuclease having a sequence SEQ ID NO: 16, a CRISPR repeat RNA having a sequence SEQ ID NO: 17, and a tracr RNA having a sequence SEQ ID NO: 18. 
     
     
         8 . The system for CRISPR editing of live cells of  claim 1 , a MAD2022 nuclease having a sequence SEQ ID NO: 19, a CRISPR repeat RNA having a sequence SEQ ID NO: 20, and a tracr RNA having a sequence SEQ ID NO: 21.

Join the waitlist — get patent alerts

Track US2022213458A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.